NEJM study found Zetia uptake rose quicker in US vs. Canada

Share this article:
A New England Journal of Medicine study found Zetia uptake rose much more quickly after introduction in the US than in Canada, and suggested DTC was the main culprit. “Despite the absence of data regarding clinical outcomes, ezetimibe was heavily promoted,” the study's authors wrote, citing Nielsen numbers showing that more than $200 million was spent advertising Vytorin to US consumers in 2007, while consumer ads are prohibited in Canada.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.